-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ICU Medical (NASDAQ:ICUI) Raised to "Hold" at StockNews.com
ICU Medical (NASDAQ:ICUI) Raised to "Hold" at StockNews.com
StockNews.com upgraded shares of ICU Medical (NASDAQ:ICUI – Get Rating) from a sell rating to a hold rating in a research note published on Monday.
Several other equities research analysts also recently commented on ICUI. KeyCorp reduced their target price on shares of ICU Medical from $230.00 to $225.00 in a research note on Tuesday, August 9th. TheStreet cut ICU Medical from a b- rating to a c rating in a report on Wednesday, May 11th. Finally, Raymond James cut their price target on ICU Medical from $208.00 to $190.00 and set an outperform rating for the company in a report on Tuesday, August 9th.
Get ICU Medical alerts:ICU Medical Trading Up 1.9 %
Shares of ICU Medical stock opened at $168.50 on Monday. The company's fifty day simple moving average is $168.49 and its 200-day simple moving average is $191.80. The company has a market cap of $4.03 billion, a price-to-earnings ratio of 401.20 and a beta of 0.57. The company has a current ratio of 2.45, a quick ratio of 1.25 and a debt-to-equity ratio of 0.78. ICU Medical has a 1 year low of $154.73 and a 1 year high of $259.93.
ICU Medical (NASDAQ:ICUI – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The medical instruments supplier reported $1.37 earnings per share for the quarter, missing analysts' consensus estimates of $1.68 by ($0.31). ICU Medical had a return on equity of 6.97% and a net margin of 0.31%. The business had revenue of $561.00 million for the quarter, compared to analyst estimates of $569.30 million. During the same quarter in the prior year, the firm earned $1.57 EPS. The firm's quarterly revenue was up 74.4% on a year-over-year basis. As a group, sell-side analysts expect that ICU Medical will post 5.23 EPS for the current year.Hedge Funds Weigh In On ICU Medical
Several institutional investors and hedge funds have recently modified their holdings of the business. Verition Fund Management LLC grew its position in shares of ICU Medical by 402.8% in the 2nd quarter. Verition Fund Management LLC now owns 6,385 shares of the medical instruments supplier's stock valued at $1,050,000 after purchasing an additional 5,115 shares during the period. Legal & General Group Plc grew its position in shares of ICU Medical by 2.5% in the 2nd quarter. Legal & General Group Plc now owns 48,331 shares of the medical instruments supplier's stock valued at $7,945,000 after purchasing an additional 1,158 shares during the period. Macquarie Group Ltd. grew its position in shares of ICU Medical by 23.5% in the 2nd quarter. Macquarie Group Ltd. now owns 800 shares of the medical instruments supplier's stock valued at $132,000 after purchasing an additional 152 shares during the period. Captrust Financial Advisors grew its position in shares of ICU Medical by 4.5% in the 2nd quarter. Captrust Financial Advisors now owns 1,327 shares of the medical instruments supplier's stock valued at $218,000 after purchasing an additional 57 shares during the period. Finally, Tamarack Advisers LP acquired a new position in shares of ICU Medical in the 2nd quarter valued at approximately $2,137,000. 90.20% of the stock is currently owned by institutional investors and hedge funds.
About ICU Medical
(Get Rating)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs.
Further Reading
- Get a free copy of the StockNews.com research report on ICU Medical (ICUI)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com upgraded shares of ICU Medical (NASDAQ:ICUI – Get Rating) from a sell rating to a hold rating in a research note published on Monday.
斯托克新闻网在周一发布的一份研究报告中将ICU Medical(纳斯达克代码:ICUI-GET Rating)的股票评级从卖出评级上调为持有评级。
Several other equities research analysts also recently commented on ICUI. KeyCorp reduced their target price on shares of ICU Medical from $230.00 to $225.00 in a research note on Tuesday, August 9th. TheStreet cut ICU Medical from a b- rating to a c rating in a report on Wednesday, May 11th. Finally, Raymond James cut their price target on ICU Medical from $208.00 to $190.00 and set an outperform rating for the company in a report on Tuesday, August 9th.
其他几位股票研究分析师最近也对ICUI发表了评论。KeyCorp在8月9日周二的一份研究报告中将ICU Medical的目标股价从230.00美元下调至225.00美元。华尔街在5月11日星期三的一份报告中将ICU医疗的评级从B级下调至C级。最后,雷蒙德·詹姆斯将ICU Medical的目标价从208.00美元下调至190.00美元,并在8月9日周二的一份报告中为该公司设定了表现优于预期的评级。
ICU Medical Trading Up 1.9 %
ICU医疗交易上涨1.9%
Shares of ICU Medical stock opened at $168.50 on Monday. The company's fifty day simple moving average is $168.49 and its 200-day simple moving average is $191.80. The company has a market cap of $4.03 billion, a price-to-earnings ratio of 401.20 and a beta of 0.57. The company has a current ratio of 2.45, a quick ratio of 1.25 and a debt-to-equity ratio of 0.78. ICU Medical has a 1 year low of $154.73 and a 1 year high of $259.93.
重症监护病房医疗股票周一开盘报168.50美元。该公司的50日简单移动均线切入位在168.49美元,200日简单移动均线切入位在191.80美元。该公司市值为40.3亿美元,市盈率为401.20,贝塔系数为0.57.该公司的流动比率为2.45,速动比率为1.25,债务权益比率为0.78。ICU Medical的一年低点为154.73美元,一年高位为259.93美元。
Hedge Funds Weigh In On ICU Medical
对冲基金参与ICU医疗
Several institutional investors and hedge funds have recently modified their holdings of the business. Verition Fund Management LLC grew its position in shares of ICU Medical by 402.8% in the 2nd quarter. Verition Fund Management LLC now owns 6,385 shares of the medical instruments supplier's stock valued at $1,050,000 after purchasing an additional 5,115 shares during the period. Legal & General Group Plc grew its position in shares of ICU Medical by 2.5% in the 2nd quarter. Legal & General Group Plc now owns 48,331 shares of the medical instruments supplier's stock valued at $7,945,000 after purchasing an additional 1,158 shares during the period. Macquarie Group Ltd. grew its position in shares of ICU Medical by 23.5% in the 2nd quarter. Macquarie Group Ltd. now owns 800 shares of the medical instruments supplier's stock valued at $132,000 after purchasing an additional 152 shares during the period. Captrust Financial Advisors grew its position in shares of ICU Medical by 4.5% in the 2nd quarter. Captrust Financial Advisors now owns 1,327 shares of the medical instruments supplier's stock valued at $218,000 after purchasing an additional 57 shares during the period. Finally, Tamarack Advisers LP acquired a new position in shares of ICU Medical in the 2nd quarter valued at approximately $2,137,000. 90.20% of the stock is currently owned by institutional investors and hedge funds.
几家机构投资者和对冲基金最近调整了对该公司的持股。Verition Fund Management LLC在第二季度持有的ICU Medical股票增加了402.8%。Verition Fund Management LLC现在拥有这家医疗器械供应商的6,385股股票,价值1,050,000美元,在此期间又购买了5,115股。Legal&General Group Plc在第二季度持有的ICU Medical股票增加了2.5%。Legal&General Group Plc现在拥有这家医疗器械供应商的48,331股股票,价值794.5万美元,在此期间又购买了1,158股。第二季度,麦格理集团(Macquarie Group Ltd.)持有的ICU医疗股份增加了23.5%。麦格理集团(Macquarie Group Ltd.)在此期间又购买了152股,目前持有这家医疗器械供应商800股股票,价值13.2万美元。CapTrust Financial Advisors在第二季度将其在ICU Medical的股票头寸增加了4.5%。CapTrust Financial Advisors现在拥有这家医疗器械供应商1,327股股票,价值21.8万美元,在此期间又购买了57股。最后,Tamarack Advisers LP在第二季度收购了ICU Medical的新头寸,价值约为2137,000美元。90.20%的股票目前由机构投资者和对冲基金持有。
About ICU Medical
关于ICU医疗
(Get Rating)
(获取评级)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs.
ICU医疗公司及其子公司在全球范围内开发、制造和销售用于输液治疗和危重护理应用的医疗设备。该公司的输液治疗产品包括MicroClave、MicroClave Clear和NanoClave品牌的无针产品;中子导管通畅设备;SwabCap和SwabTip消毒帽;Tego血液透析连接器;ClearGuard HD,血液透析导管的抗菌屏障帽;ChemoClave和ChemoLock封闭式系统传输设备,以及用于制备危险药物的Diana危险药物复合系统。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on ICU Medical (ICUI)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- 免费获取StockNews.com关于ICU医学的研究报告(ICUI)
- 石油和天然气股票:投资可再生能源的安全途径
- 这些绿色能源公司适合你的投资组合吗?
- 希捷科技的宿醉何时才能结束?
- 安相能源有足够的动力继续提高动力吗?
- 独一无二的氢燃料电池库存
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受ICU医学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ICU医疗及相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧